Show simple item record

dc.contributor.authorLee, S.
dc.contributor.authorLaiman, A.
dc.contributor.authorFrench, M.
dc.contributor.authorFlexman, J.
dc.contributor.authorWatson, M.
dc.contributor.authorPrice, Patricia
dc.identifier.citationLee, S. and Laiman, A. and French, M. and Flexman, J. and Watson, M. and Price, P. 2017. The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy. Clinical Immunology. 179: pp. 54-63.

Antibody responses have not been fully characterised in chronically HIV/HCV patients receiving antiretroviral therapy (ART). Seventeen HIV/HCV patients receiving ART were followed for a median (range) interval of 597 (186–766) weeks. Prior to ART, HIV/HCV patients had lower levels of antibodies reactive with HCV core and JFH-1, and lower genotype cross-reactive neutralising antibodies (nAb) titres, than HCV patients. Levels of JFH-1 reactive antibody increased on ART, irrespective of CD4+ T-cell counts or changes in serum ALT levels. The appearance of nAb coincided with control of HCV viral replication in five HIV/HCV patients. In other patients, HCV viral loads remained elevated despite nAb responses. Sustained virological responses following HCV therapy were associated with reduced antibody responses to JFH-1 and core but elevated responses to non-structural proteins. We conclude that nAb responses alone may fail to clear HCV, but contribute to control of viral replication in some HIV/HCV patients responding to ART.

dc.publisherAcademic Press
dc.titleThe dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy
dc.typeJournal Article
dcterms.source.titleClinical Immunology
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusOpen access

Files in this item


This item appears in the following Collection(s)

Show simple item record